Skip to main content
博迅生物 logo

博迅生物 — Investor Relations & Filings

Ticker · 920504 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 301 across all filing types
Latest filing 2025-08-20 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920504

About 博迅生物

http://www.boxun.com.cn/

Boxun Medical Biological Instrument Corp. specializes in the development and manufacture of laboratory equipment and medical instruments. The company's core product line includes high-pressure steam sterilizers, constant temperature incubators, CO2 incubators, drying ovens, and environmental test chambers. These instruments are designed for applications in life sciences, healthcare, pharmaceutical research, and environmental monitoring. Boxun focuses on delivering precise thermal control and reliable sterilization solutions, ensuring compliance with international quality standards. Its equipment is utilized in scientific research, clinical diagnostics, and industrial quality control to maintain sterile environments and stable experimental conditions. The company emphasizes technical innovation and product durability to support the requirements of modern laboratory facilities.

Recent filings

Filing Released Lang Actions
第四届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shanghai Boxun Medical Biological Instruments Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on corporate governance matters such as the cancellation of the Supervisory Board, changes in business scope, and appointment of the audit firm. It is not a full annual report, audit report, or financial statement. It is also not a shareholder meeting voting result announcement (DVA) since it is a Supervisory Board meeting resolution. The document is a formal announcement of board/management decisions and changes, fitting the category of Board/Management Information (MANG). The document length is short and contains detailed resolutions, not just a notice or announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is MANG with high confidence.
2025-08-20 Chinese
内幕信息知情人登记管理制度
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记管理制度' which translates to 'Insider Information Insider Registration Management System'. It details the company's internal rules and procedures for managing insider information, including responsibilities of the board, confidentiality obligations, and regulatory compliance. The document references laws and regulations such as the Company Law, Securities Law, and Beijing Stock Exchange rules. It is a detailed governance-related policy document rather than a financial report, earnings release, or announcement. It does not contain financial data or results, nor is it a notice or announcement of a report. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2927 characters, which is substantive for a governance policy document. Confidence is high due to the clear focus on governance and insider information management.
2025-08-20 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's use of idle funds to purchase financial products, including specifics on amounts, counterparties, risk controls, and approvals. It is a regulatory disclosure about financing activities, specifically the purchase of wealth management products using the company's own funds. It does not contain financial statements or earnings data, nor is it a report or presentation. It is not a simple announcement of a report publication but a substantive update on capital usage and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (5036 characters) supports it being a full announcement rather than a brief notice.
2025-08-03 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Boxun Medical Biological Instruments Co., Ltd. regarding the progress of using idle raised funds for cash management. It details the board meeting approval, amounts involved, types of financial products purchased, risk controls, and compliance with disclosure rules. The document is a disclosure about ongoing cash management activities using idle raised funds, including amounts, counterparties, and risk management, but it does not contain financial statements or comprehensive financial analysis. It is a regulatory disclosure about capital/financing activities related to the use of raised funds for cash management. The document length is 3353 characters, which is relatively short and focused on a specific financing-related update rather than a full financial report or audit. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-07-27 Chinese
关于变更持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for the company Shanghai Boxun Medical Biological Instruments Co., Ltd. It details the replacement of one sponsor representative with another and includes a brief resume of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of voting results or other report types. This is a management-related announcement about changes in the company's sponsor representatives, which aligns with Board/Management Information filings. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and focused on personnel change, not a full report or regulatory filing.
2025-07-24 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Boxun Medical Biological Instrument Co., Ltd. regarding the progress of using idle proprietary funds to purchase wealth management products. It details the authorization, amounts, counterparties, risk controls, and status of these financial products. The content focuses on financing activities related to the company's capital management rather than financial results, management changes, or regulatory filings. It is not a full financial report, earnings release, or audit report. The document is a specific update on capital usage and financing activities, fitting the definition of a Capital/Financing Update (CAP). The document length is about 4,831 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2025-07-03 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.